{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:22:45Z","timestamp":1778811765629,"version":"3.51.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Asthma is a common chronic inflammatory disease in children. Pediatric asthma has a wide range of immunologic phenotypes and different treatment responses. Recent data from various studies suggest that the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, a cytosolic multiprotein complex, has a central role in innate immunity, may be implicated in pediatric asthma pathogenesis, especially in the neutrophilic corticosteroid-resistant type. This review article investigates the mechanism of NLRP3 inflammasome activation as well as its role in airway inflammation and its expression in pediatric asthma based on sputum studies. The findings emphasize an association between elevated NLRP3 levels and poor asthma control. The need for novel treatments is important because Current using therapies such as corticosteroids and biologics demonstrate variable efficacy. According to data, their efficacy heavily depends on the underlying inflammatory phenotype. Biologics such as mepolizumab, benralizumab, and dupilumab are well known for their corticosteroid-sparing effects especially in cases of severe eosinophilic asthma. even though, their therapeutic benefits are limited when it comes to neutrophilic or steroid-resistant phenotypes. NLRP3 inhibitors are new, promising treatments which emerged recently and show potential capability in reducing airway inflammation in animal models. Furthermore, NLRP3-driven inflammation appears to play a role not only in asthma but also in inflammatory bowel disease and juvenile idiopathic arthritis, indicating a wider relevance for therapies that target the inflammasome pathway. Although promising data, application of this data in clinical practice is still challenging due to many causes, including diagnostic challenges, ethical considerations in trials involving children, and the lack of approved NLRP3 inhibitors for use in children. More research is required and essential to confirm that NLRP3 could be used as a biomarker or therapeutic target in pediatric asthma.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s13223-025-01001-1","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T19:26:54Z","timestamp":1764444414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["NLRP3 inflammasome expression in pediatric asthma: sputum-based insights, inflammatory mechanisms, and targeted therapeutic strategies"],"prefix":"10.1186","volume":"22","author":[{"given":"Mohammed","family":"AbuBaha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Aldwaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bara","family":"Abubaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar","family":"Zahran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Sandouka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kareem","family":"Istetieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam","family":"Hamshary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abushehadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Saife","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeen","family":"Sandoqah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"issue":"12","key":"1001_CR1","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.3390\/ijms21124223","volume":"21","author":"R Fusco","year":"2020","unstructured":"Fusco R, Siracusa R, Genovese T, Cuzzocrea S, Di Paola R. Focus on the role of NLRP3 inflammasome in diseases. Int J Mol Sci. 2020;21(12):4223.","journal-title":"Int J Mol Sci"},{"key":"1001_CR2","doi-asserted-by":"crossref","first-page":"100889","DOI":"10.1016\/j.mam.2020.100889","volume":"76","author":"L Wang","year":"2020","unstructured":"Wang L, Hauenstein AV. The NLRP3 inflammasome: mechanism of action, role in disease and therapies. Mol Aspects Med. 2020;76:100889.","journal-title":"Mol Aspects Med"},{"issue":"4","key":"1001_CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","volume":"48","author":"J Xu","year":"2023","unstructured":"Xu J, N\u00fa\u00f1ez G. The NLRP3 inflammasome: activation and regulation. Trends Biochem Sci. 2023;48(4):331\u201344.","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"1001_CR4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JPY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477\u201389.","journal-title":"Nat Rev Immunol"},{"key":"1001_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1109938\/full","author":"X Zhan","year":"2023","unstructured":"Zhan X, Li Q, Xu G, Xiao X, Bai Z. The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2022.1109938\/full.","journal-title":"Front Immunol"},{"issue":"3","key":"1001_CR6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/pharmrev.122.000629","volume":"75","author":"Q Ma","year":"2023","unstructured":"Ma Q. Pharmacological inhibition of the NLRP3 inflammasome: structure, molecular activation, and inhibitor-NLRP3 interaction. Pharmacol Rev. 2023;75(3):487\u2013520.","journal-title":"Pharmacol Rev"},{"key":"1001_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.879021\/full","author":"HM Blevins","year":"2025","unstructured":"Blevins HM, Xu Y, Biby S, Zhang S. The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci. 2025. https:\/\/doi.org\/10.3389\/fnagi.2022.879021\/full.","journal-title":"Front Aging Neurosci"},{"issue":"23","key":"1001_CR8","doi-asserted-by":"crossref","first-page":"jsc248344","DOI":"10.1242\/jcs.248344","volume":"133","author":"AN Weber","year":"2020","unstructured":"Weber AN, Bittner ZA, Shankar S, Liu X, Chang TH, Jin T, et al. Recent insights into the regulatory networks of NLRP3 inflammasome activation. J Cell Sci. 2020;133(23):jsc248344.","journal-title":"J Cell Sci"},{"issue":"12","key":"1001_CR9","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.3390\/ijms21124294","volume":"21","author":"G Zito","year":"2020","unstructured":"Zito G, Buscetta M, Cimino M, Dino P, Bucchieri F, Cipollina C. Cellular models and assays to study NLRP3 inflammasome biology. Int J Mol Sci. 2020;21(12):4294.","journal-title":"Int J Mol Sci"},{"key":"1001_CR10","doi-asserted-by":"crossref","first-page":"110542","DOI":"10.1016\/j.biopha.2020.110542","volume":"130","author":"Z Li","year":"2020","unstructured":"Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130:110542.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1001_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3892\/ijmm.2023.5238","volume":"51","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wang Z, Zheng Y, Yu Q, Zeng M, Bai L, et al. Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases. Int J Mol Med. 2023;51(4):35. https:\/\/doi.org\/10.3892\/ijmm.2023.5238.","journal-title":"Int J Mol Med"},{"issue":"3","key":"1001_CR12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1124\/pharmrev.120.000171","volume":"73","author":"SE Corcoran","year":"2021","unstructured":"Corcoran SE, Halai R, Cooper MA. Pharmacological inhibition of the Nod-like receptor family pyrin domain containing 3 inflammasome with MCC950. Pharmacol Rev. 2021;73(3):968\u20131000.","journal-title":"Pharmacol Rev"},{"issue":"7944","key":"1001_CR13","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41586-022-05570-8","volume":"613","author":"L Xiao","year":"2023","unstructured":"Xiao L, Magupalli VG, Wu H. Cryo-EM structures of the active NLRP3 inflammasome disc. Nature. 2023;613(7944):595\u2013600.","journal-title":"Nature"},{"key":"1001_CR14","unstructured":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome | Nature [Internet]. [cited 2025 Jul 16]. Available from: https:\/\/www.nature.com\/articles\/s41586-019-1295-z"},{"key":"1001_CR15","unstructured":"Kv S, M D, Jp T. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. PubMed [Internet]. [cited 2025 Jul 16]; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31036962\/"},{"issue":"1","key":"1001_CR16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imr.12908","volume":"297","author":"D Chauhan","year":"2020","unstructured":"Chauhan D, Vande Walle L, Lamkanfi M. Therapeutic modulation of inflammasome pathways. Immunol Rev. 2020;297(1):123\u201338.","journal-title":"Immunol Rev"},{"issue":"1","key":"1001_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1074\/jbc.C115.700492","volume":"291","author":"JL Schmid-Burgk","year":"2016","unstructured":"Schmid-Burgk JL, Chauhan D, Schmidt T, Ebert TS, Reinhardt J, Endl E, et al. A Genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation. J Biol Chem. 2016;291(1):103\u20139.","journal-title":"J Biol Chem"},{"issue":"1","key":"1001_CR18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/cmi.2016.11","volume":"14","author":"JS Bezbradica","year":"2017","unstructured":"Bezbradica JS, Coll RC, Schroder K. Sterile signals generate weaker and delayed macrophage NLRP3 inflammasome responses relative to microbial signals. Cell Mol Immunol. 2017;14(1):118\u201326.","journal-title":"Cell Mol Immunol"},{"key":"1001_CR19","volume-title":"The Inflammasomes Progress in Inflammation Research","author":"K Labb\u00e9","year":"2011","unstructured":"Labb\u00e9 K, Saleh M. Pyroptosis: A Caspase-1-Dependent Programmed Cell Death and a Barrier to Infection. In: Couillin I, P\u00e9trilli V, Martinon F, editors. The Inflammasomes Progress in Inflammation Research. Basel: Springer; 2011."},{"key":"1001_CR20","doi-asserted-by":"crossref","first-page":"1178662","DOI":"10.3389\/fimmu.2023.1178662","volume":"14","author":"Z Dai","year":"2023","unstructured":"Dai Z, Liu WC, Chen XY, Wang X, Li JL, Zhang X. Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors. Front Immunol. 2023;14:1178662.","journal-title":"Front Immunol"},{"issue":"7","key":"1001_CR21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3390\/biology12070943","volume":"12","author":"JA Cerato","year":"2023","unstructured":"Cerato JA, da Silva EF, Porto BN. Breaking bad: inflammasome activation by respiratory viruses. Biology. 2023;12(7):943.","journal-title":"Biology"},{"issue":"1","key":"1001_CR22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10238-024-01492-z","volume":"24","author":"H Zhou","year":"2024","unstructured":"Zhou H, Wang L, Lv W, Yu H. The NLRP3 inflammasome in allergic diseases: mechanisms and therapeutic implications. Clin Exp Med. 2024;24(1):231.","journal-title":"Clin Exp Med"},{"issue":"10","key":"1001_CR23","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3390\/jcm8101615","volume":"8","author":"E Theofani","year":"2019","unstructured":"Theofani E, Semitekolou M, Morianos I, Samitas K, Xanthou G. Targeting NLRP3 inflammasome activation in severe asthma. J Clin Med. 2019;8(10):1615.","journal-title":"J Clin Med"},{"issue":"341","key":"1001_CR24","doi-asserted-by":"crossref","first-page":"122997","DOI":"10.1016\/j.envpol.2023.122997","volume":"15","author":"L Caceres","year":"2024","unstructured":"Caceres L, Abogunloko T, Malchow S, Ehret F, Merz J, Li X, et al. Molecular mechanisms underlying NLRP3 inflammasome activation and IL-1\u03b2 production in air pollution fine particulate matter (PM25)-primed macrophages. Environ Pollut. 2024;15(341):122997.","journal-title":"Environ Pollut"},{"issue":"5","key":"1001_CR25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3904\/kjim.2016.033","volume":"32","author":"ST Uh","year":"2017","unstructured":"Uh ST, Koo SM, Kim Y, Kim K, Park S, Jang AS, et al. The activation of NLRP3-inflammsome by stimulation of diesel exhaust particles in lung tissues from emphysema model and RAW 264.7 cell line. Korean J Internal Med. 2017;32(5):865.","journal-title":"Korean J Internal Med"},{"issue":"1","key":"1001_CR26","first-page":"9444227","volume":"2022","author":"L Chen","year":"2022","unstructured":"Chen L, Hou W, Liu F, Zhu R, Lv A, Quan W, et al. Blockade of NLRP3\/Caspase-1\/IL-1\u03b2 Regulated Th17\/Treg immune imbalance and attenuated the neutrophilic airway inflammation in an ovalbumin-induced murine model of asthma. J Immunol Res. 2022;2022(1):9444227.","journal-title":"J Immunol Res"},{"issue":"221","key":"1001_CR27","doi-asserted-by":"crossref","first-page":"112433","DOI":"10.1016\/j.ecoenv.2021.112433","volume":"15","author":"R Xiong","year":"2021","unstructured":"Xiong R, Jiang W, Li N, Liu B, He R, Wang B, et al. PM25-induced lung injury is attenuated in macrophage-specific NLRP3-deficient mice. Ecotoxicol Environ Saf. 2021;15(221):112433.","journal-title":"Ecotoxicol Environ Saf"},{"issue":"3","key":"1001_CR28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3892\/ijmm.2025.5489","volume":"55","author":"H Wang","year":"2025","unstructured":"Wang H, Ma L, Su W, Liu Y, Xie N, Liu J. NLRP3 inflammasome in health and disease. Int J Mol Med. 2025;55(3):48.","journal-title":"Int J Mol Med"},{"key":"1001_CR29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3389\/fphys.2014.00352","volume":"5","author":"A Harijith","year":"2014","unstructured":"Harijith A, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation. Front Physiol. 2014;5:352.","journal-title":"Front Physiol"},{"issue":"1","key":"1001_CR30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s40001-024-02114-w","volume":"29","author":"F Li","year":"2024","unstructured":"Li F, Liu Z. Expression of NLRP3 in serum and induced sputum of children with asthma and their relationship with disease severity. Eur J Med Res. 2024;29(1):526.","journal-title":"Eur J Med Res"},{"key":"1001_CR31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molimm.2022.03.118","volume":"146","author":"YC Xiu","year":"2022","unstructured":"Xiu YC, An SZ, Chun OG, Ju CX, Liu Q, Zeng D, et al. Maresin-2 alleviates allergic airway inflammation in mice by inhibiting the activation of NLRP3 inflammasome, Th2 type immune response and oxidative stress. Mol Immunol. 2022;146:78\u201386.","journal-title":"Mol Immunol"},{"issue":"4","key":"1001_CR32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jmcb\/mjv012","volume":"7","author":"F Madouri","year":"2015","unstructured":"Madouri F, Guillou N, Fauconnier L, Marchiol T, Rouxel N, Chenuet P, et al. Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation. J Mol Cell Biol. 2015;7(4):351\u201365.","journal-title":"J Mol Cell Biol"},{"issue":"1","key":"1001_CR33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12931-023-02603-2","volume":"24","author":"JC Horvat","year":"2023","unstructured":"Horvat JC, Kim RY, Weaver N, Augood C, Brown AC, Donovan C, et al. Characterization and inhibition of inflammasome responses in severe and non-severe asthma. Respir Res. 2023;24(1):303.","journal-title":"Respir Res"},{"issue":"1","key":"1001_CR34","doi-asserted-by":"crossref","first-page":"111941","DOI":"10.1016\/j.celrep.2022.111941","volume":"42","author":"AK Meyers","year":"2023","unstructured":"Meyers AK, Wang Z, Han W, Zhao Q, Zabalawi M, Duan L, et al. Pyruvate dehydrogenase kinase supports macrophage NLRP3 inflammasome activation during acute inflammation. Cell Rep. 2023;42(1):111941.","journal-title":"Cell Rep"},{"issue":"1","key":"1001_CR35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4049\/jimmunol.1100500","volume":"187","author":"JL Ather","year":"2011","unstructured":"Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE, et al. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol. 2011;187(1):64\u201373.","journal-title":"J Immunol"},{"key":"1001_CR36","doi-asserted-by":"crossref","first-page":"1282782","DOI":"10.3389\/falgy.2023.1282782","volume":"4","author":"B Goncalves","year":"2023","unstructured":"Goncalves B, Eze UA. Sputum induction and its diagnostic applications in inflammatory airway disorders: a review. Front Allergy. 2023;4:1282782.","journal-title":"Front Allergy"},{"key":"1001_CR37","unstructured":"Shen F, Zubair M, Sergi C. Sputum Analysis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;2025"},{"key":"1001_CR38","doi-asserted-by":"crossref","unstructured":"Weiszhar Z, Horvath I. Induced sputum analysis: step by step. 2013 Jun 1 [cited 2025 Jul 16]; Available from: https:\/\/publications.ersnet.org\/content\/breathe\/9\/4\/300","DOI":"10.1183\/20734735.042912"},{"issue":"4","key":"1001_CR39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1183\/09031936.00105013","volume":"43","author":"JL Simpson","year":"2014","unstructured":"Simpson JL, Phipps S, Baines KJ, Oreo KM, Gunawardhana L, Gibson PG. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J. 2014;43(4):1067\u201376.","journal-title":"Eur Respir J"},{"issue":"3","key":"1001_CR40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1164\/rccm.201609-1830OC","volume":"196","author":"RY Kim","year":"2017","unstructured":"Kim RY, Pinkerton JW, Essilfie AT, Robertson AA, Baines KJ, Brown AC, et al. Role for NLRP3 inflammasome\u2013mediated, IL-1\u03b2\u2013dependent responses in severe, steroid-resistant asthma. Am J Respir Crit Care Med. 2017;196(3):283\u201397.","journal-title":"Am J Respir Crit Care Med"},{"issue":"69","key":"1001_CR41","doi-asserted-by":"crossref","first-page":"109523","DOI":"10.1016\/j.cellsig.2019.109523","volume":"1","author":"DP Potaczek","year":"2020","unstructured":"Potaczek DP, Miethe S, Schindler V, Alhamdan F, Garn H. Role of airway epithelial cells in the development of different asthma phenotypes. Cell Signal. 2020;1(69):109523.","journal-title":"Cell Signal"},{"issue":"3","key":"1001_CR42","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jaip.2023.09.023","volume":"12","author":"LX He","year":"2024","unstructured":"He LX, Deng K, Wang J, Zhang X, Wang L, Zhang HP, et al. Clinical subtypes of neutrophilic asthma: a cluster analysis from Australasian severe asthma network. J Allergy Clin Immun Pract. 2024;12(3):686\u201398.","journal-title":"J Allergy Clin Immun Pract"},{"issue":"1","key":"1001_CR43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12931-025-03266-x","volume":"26","author":"SL Taylor","year":"2025","unstructured":"Taylor SL, Brooks CR, Elms L, Manning SK, Richard A, Burmanje J, et al. Sputum quality affects assessment of airway microbiology in childhood asthma. Respir Res. 2025;26(1):209.","journal-title":"Respir Res"},{"issue":"4","key":"1001_CR44","doi-asserted-by":"crossref","first-page":"045001","DOI":"10.1088\/1752-7163\/ad7a9a","volume":"18","author":"M Maniscalco","year":"2024","unstructured":"Maniscalco M, Candia C, Fuschillo S, Ambrosino P, Paris D, Motta A. Exhaled breath condensate (EBC) in respiratory diseases: recent advances and future perspectives in the age of omic sciences. J Breath Res. 2024;18(4):045001.","journal-title":"J Breath Res"},{"issue":"13","key":"1001_CR45","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.3390\/ijms25137395","volume":"25","author":"K Kita","year":"2024","unstructured":"Kita K, Gawinowska M, Che\u0142mi\u0144ska M, Niedoszytko M. The role of exhaled breath condensate in chronic inflammatory and neoplastic diseases of the respiratory tract. Int J Mol Sci. 2024;25(13):7395.","journal-title":"Int J Mol Sci"},{"key":"1001_CR46","unstructured":"Researchers develop nasal swab test that can detect specific asthma subtypes in kids | NHLBI, NIH [Internet]. 2025 [cited 2025 Jul 17]. Available from: https:\/\/www.nhlbi.nih.gov\/news\/2025\/researchers-develop-nasal-swab-test-can-detect-specific-asthma-subtypes-kids"},{"key":"1001_CR47","unstructured":"Non-Invasive Nasal Swab Can Diagnose Specific Asthma Endotype in Young Patients [Internet]. [cited 2025 Jul 17]. Available from: https:\/\/www.pharmacytimes.com\/view\/non-invasive-nasal-swab-can-diagnose-specific-asthma-endotype-in-young-patients"},{"issue":"4","key":"1001_CR48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jama.2024.22684","volume":"333","author":"M Yue","year":"2025","unstructured":"Yue M, Gaietto K, Han YY, Rosser FJ, Xu Z, Qoyawayma C, et al. Transcriptomic profiles in nasal epithelium and asthma Endotypes in youth. JAMA. 2025;333(4):307\u201318.","journal-title":"JAMA"},{"key":"1001_CR49","doi-asserted-by":"crossref","first-page":"1435892","DOI":"10.3389\/fimmu.2024.1435892","volume":"15","author":"HF Lu","year":"2024","unstructured":"Lu HF, Zhou YC, Hu TY, Yang DH, Wang XJ, Luo DD, et al. Unraveling the role of NLRP3 inflammasome in allergic inflammation: implications for novel therapies. Front Immunol. 2024;15:1435892.","journal-title":"Front Immunol"},{"key":"1001_CR50","doi-asserted-by":"crossref","first-page":"1486780","DOI":"10.3389\/fmed.2024.1486780","volume":"11","author":"S Thawanaphong","year":"2024","unstructured":"Thawanaphong S, Nair A, Volfson E, Nair P, Mukherjee M. IL-18 biology in severe asthma. Front Med. 2024;11:1486780.","journal-title":"Front Med"},{"issue":"18","key":"1001_CR51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2147\/JAA.S526788","volume":"22","author":"X Cai","year":"2025","unstructured":"Cai X. NOD2-NLRP3 axis and asthma. J Asthma Allergy. 2025;22(18):769\u201377.","journal-title":"J Asthma Allergy"},{"issue":"1","key":"1001_CR52","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1038\/s41467-023-37470-4","volume":"14","author":"U Radzikowska","year":"2023","unstructured":"Radzikowska U, Eljaszewicz A, Tan G, Stocker N, Heider A, Westermann P, et al. Rhinovirus-induced epithelial RIG-I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID-19. Nat Commun. 2023;14(1):2329.","journal-title":"Nat Commun"},{"key":"1001_CR53","doi-asserted-by":"crossref","first-page":"1393819","DOI":"10.3389\/fimmu.2024.1393819","volume":"15","author":"R Bauer","year":"2024","unstructured":"Bauer R, Dang HH, Neureiter D, Unger MS, Neuper T, Jensen M, et al. NLRP3 promotes allergic responses to birch pollen extract in a model of intranasal sensitization. Front Immunol. 2024;15:1393819.","journal-title":"Front Immunol"},{"issue":"1","key":"1001_CR54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12950-024-00388-9","volume":"21","author":"D Mar\u00edn-Palma","year":"2024","unstructured":"Mar\u00edn-Palma D, Tabares-Guevara JH, Taborda N, Rugeles MT, Hernandez JC. Coarse particulate matter (PM10) induce an inflammatory response through the NLRP3 activation. J Inflamm. 2024;21(1):15.","journal-title":"J Inflamm"},{"key":"1001_CR55","doi-asserted-by":"crossref","first-page":"1006654","DOI":"10.3389\/fimmu.2022.1006654","volume":"13","author":"K Leszczy\u0144ska","year":"2022","unstructured":"Leszczy\u0144ska K, Jakubczyk D, Gorska S. The NLRP3 inflammasome as a new target in respiratory disorders treatment. Front Immunol. 2022;13:1006654.","journal-title":"Front Immunol"},{"issue":"6","key":"1001_CR56","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2500\/aap.2019.40.4254","volume":"40","author":"AL Devonshire","year":"2019","unstructured":"Devonshire AL, Kumar R. Pediatric asthma: principles and treatment. Allergy Asthma Proc. 2019;40(6):389\u201392.","journal-title":"Allergy Asthma Proc"},{"issue":"22","key":"1001_CR57","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/jama.2020.21974","volume":"324","author":"MM Cloutier","year":"2020","unstructured":"Cloutier MM, Dixon AE, Krishnan JA, Lemanske RF, Pace W, Schatz M. Managing asthma in adolescents and adults: 2020 asthma guideline update from the national asthma education and prevention program. JAMA. 2020;324(22):2301.","journal-title":"JAMA"},{"issue":"5","key":"1001_CR58","first-page":"364","volume":"121","author":"S Dubin","year":"2024","unstructured":"Dubin S, Patak P, Jung D. Update on asthma management guidelines. Mo Med. 2024;121(5):364\u20137.","journal-title":"Mo Med"},{"issue":"5","key":"1001_CR59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/ewjm.175.5.303","volume":"175","author":"ML Abrolat","year":"2001","unstructured":"Abrolat ML, Nguyen LP, Saca LF. Hold it! Correct use of inhalers in children with asthma. West J Med. 2001;175(5):303\u20134.","journal-title":"West J Med"},{"issue":"6","key":"1001_CR60","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/2042098613504124","volume":"4","author":"Y Xia","year":"2013","unstructured":"Xia Y, Kelton CML, Xue L, Guo JJ, Bian B, Wigle PR. Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma. Ther Adv Drug Saf. 2013;4(6):254\u201363.","journal-title":"Ther Adv Drug Saf"},{"issue":"10","key":"1001_CR61","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1034\/j.1398-9995.2001.00100.x","volume":"56","author":"JC Dubus","year":"2001","unstructured":"Dubus JC, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy. 2001;56(10):944\u20138.","journal-title":"Allergy"},{"issue":"5","key":"1001_CR62","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12098-023-04706-6","volume":"91","author":"LS Hema","year":"2024","unstructured":"Hema LS, Kumar P, Goyal JP, Vyas V, Singh K. Effect of long-term inhaled corticosteroids on the hypothalamic-pituitary-adrenal axis in children with asthma. Indian J Pediatr. 2024;91(5):441\u20137.","journal-title":"Indian J Pediatr"},{"issue":"1","key":"1001_CR63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1385\/CRIAI:27:1:059","volume":"27","author":"M Hoshino","year":"2004","unstructured":"Hoshino M. Impact of inhaled corticosteroids and leukotriene receptor antagonists on airway remodeling. Clin Rev Allergy Immunol. 2004;27(1):59\u201364.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1001_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.70092","author":"S Tunca","year":"2025","unstructured":"Tunca S, Yilmaz O, Ocalan M, Arga M, Cavkaytar O, Ozceker D, et al. Potentially overlooked risk for neuropsychiatric symptoms in children: montelukast treatment. J Paediatr Child Health. 2025. https:\/\/doi.org\/10.1111\/jpc.70092.","journal-title":"J Paediatr Child Health"},{"issue":"2","key":"1001_CR65","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jaci.2015.12.1347","volume":"138","author":"CJ Bossley","year":"2016","unstructured":"Bossley CJ, Fleming L, Ullmann N, Gupta A, Adams A, Nagakumar P, et al. Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach. J Allergy Clin Immunol. 2016;138(2):413-420.e6.","journal-title":"J Allergy Clin Immunol"},{"issue":"181","key":"1001_CR66","first-page":"106360","volume":"1","author":"AH AlizadehBahmani","year":"2023","unstructured":"AlizadehBahmani AH, Slob EMA, Bloemsma LD, Brandstetter S, Corcuera-Elosegui P, Gorenjak M, et al. Medication use in uncontrolled pediatric asthma: results from the SysPharmPediA study. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2023;1(181):106360.","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci"},{"issue":"6","key":"1001_CR67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fped.2018.00432","volume":"16","author":"M Maglione","year":"2019","unstructured":"Maglione M, Poeta M, Santamaria F. New drugs for pediatric asthma. Front Pediatr. 2019;16(6):432.","journal-title":"Front Pediatr"},{"issue":"3","key":"1001_CR68","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/all.15164","volume":"77","author":"LP Lunding","year":"2022","unstructured":"Lunding LP, Skouras DB, Vock C, Dinarello CA, Wegmann M. The NLRP3 inflammasome inhibitor, OLT1177\u00ae, ameliorates experimental allergic asthma in mice. Allergy. 2022;77(3):1035\u20138.","journal-title":"Allergy"},{"issue":"10","key":"1001_CR69","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3389\/fimmu.2019.02578","volume":"1","author":"A S\u00e1nchez-Fern\u00e1ndez","year":"2019","unstructured":"S\u00e1nchez-Fern\u00e1ndez A, Skouras DB, Dinarello CA, L\u00f3pez-Vales R. OLT1177 (Dapansutrile), a Selective NLRP3 inflammasome inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis. Front Immunol. 2019;1(10):2578.","journal-title":"Front Immunol"},{"key":"1001_CR70","doi-asserted-by":"crossref","first-page":"837667","DOI":"10.3389\/fped.2022.837667","volume":"10","author":"S Ghirardo","year":"2022","unstructured":"Ghirardo S, Mazzolai M, Di Marco A, Petreschi F, Ullmann N, et al. Biological treatments and target therapies for pediatric respiratory medicine: not only asthma. Front Pediatr. 2022;10:837667.","journal-title":"Front Pediatr"},{"issue":"3","key":"1001_CR71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1753465816632638","volume":"10","author":"NC Thomson","year":"2016","unstructured":"Thomson NC. Novel approaches to the management of noneosinophilic asthma. Ther Adv Respir Dis. 2016;10(3):211\u201334.","journal-title":"Ther Adv Respir Dis"},{"issue":"2","key":"1001_CR72","doi-asserted-by":"crossref","first-page":"1900563","DOI":"10.1183\/13993003.00563-2019","volume":"55","author":"ET Osei","year":"2020","unstructured":"Osei ET, Brandsma CA, Timens W, Heijink IH, Hackett TL. Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD. Eur Respir J. 2020;55(2):1900563.","journal-title":"Eur Respir J"},{"issue":"13","key":"1001_CR73","doi-asserted-by":"crossref","first-page":"983852","DOI":"10.3389\/fimmu.2022.983852","volume":"6","author":"G Kardas","year":"2022","unstructured":"Kardas G, Panek M, Kuna P, Damia\u0144ski P, Kupczyk M. Monoclonal antibodies in the management of asthma: dead ends, current status and future perspectives. Front Immunol. 2022;6(13):983852.","journal-title":"Front Immunol"},{"issue":"9","key":"1001_CR74","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.3390\/jcm14093153","volume":"14","author":"N Faria","year":"2025","unstructured":"Faria N, Costa MI, Fernandes AL, Fernandes A, Fernandes B, Machado DC, et al. Biologic therapies for severe asthma: current insights and future directions. J Clin Med. 2025;14(9):3153.","journal-title":"J Clin Med"},{"issue":"4","key":"1001_CR75","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4062\/biomolther.2023.099","volume":"31","author":"H-J Song","year":"2023","unstructured":"Song H-J, Jeon S-G, Choi E-K, Park M, Lee W-I, Chun E, et al. NLRP3 inflammasome as therapeutic targets in inflammatory diseases. Biomol Ther (Seoul). 2023;31(4):395\u2013401. https:\/\/doi.org\/10.4062\/biomolther.2023.099.","journal-title":"Biomol Ther (Seoul)"},{"issue":"1","key":"1001_CR76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11481-024-10101-5","volume":"19","author":"T Kodi","year":"2024","unstructured":"Kodi T, Sankhe R, Gopinathan A, Nandakumar K, Kishore A. New insights on NLRP3 inflammasome: mechanisms of activation, inhibition, and epigenetic regulation. J Neuroimmune Pharmacol. 2024;19(1):7.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"13","key":"1001_CR77","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","volume":"20","author":"N Kelley","year":"2019","unstructured":"Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1001_CR78","doi-asserted-by":"crossref","first-page":"e2022058964","DOI":"10.1542\/peds.2022-058964","volume":"152","author":"VL Gennaro","year":"2023","unstructured":"Gennaro VL, Maclin J, Weiser P, Stoll ML, Smitherman EA. Juvenile idiopathic arthritis with associated inflammatory bowel Disease and CARD8 mutation. Pediatrics. 2023;152(4):e2022058964.","journal-title":"Pediatrics"},{"issue":"6","key":"1001_CR79","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s414230180024z","volume":"16","author":"HK Kim","year":"2019","unstructured":"Kim HK, Kim HJ, Kim JY, Park S, Choi Y, Lee JE. The NLRP3 inflammasome in rheumatoid arthritis: pathogenic role and therapeutic applications. Cell Mol Immunol. 2019;16(6):431\u201349. https:\/\/doi.org\/10.1038\/s414230180024z.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"1001_CR80","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/cells13050442","volume":"13","author":"DM Nicoar\u0103","year":"2024","unstructured":"Nicoar\u0103 DM, Munteanu AI, Scutca AC, Brad GF, Jug\u0103naru I, Bugi MA, et al. Examining the relationship between systemic immune\u2013inflammation index and disease severity in juvenile idiopathic arthritis. Cells. 2024;13(5):442. https:\/\/doi.org\/10.3390\/cells13050442.","journal-title":"Cells"},{"issue":"2","key":"1001_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08916934.2024.2310269","volume":"47","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang Y, Zhao X, Wang Y, Li X, Zhang H, et al. The role of NLRP3 inflammasome in type 2 inflammation related diseases. Inflammation. 2024;47(2):1\u201312. https:\/\/doi.org\/10.1080\/08916934.2024.2310269.","journal-title":"Inflammation"},{"key":"1001_CR82","doi-asserted-by":"publisher","first-page":"1006654","DOI":"10.3389\/fimmu.2022.1006654","volume":"13","author":"Y Bai","year":"2022","unstructured":"Bai Y, Zhang J, Zhang Y, Zhang Y, Liu Y, Zhang L, et al. The NLRP3 inflammasome as a new target in respiratory disorders treatment. Front Immunol. 2022;13:1006654. https:\/\/doi.org\/10.3389\/fimmu.2022.1006654.","journal-title":"Front Immunol"},{"issue":"7","key":"1001_CR83","first-page":"467","volume":"6","author":"G Giancane","year":"2016","unstructured":"Giancane G, Minoia F, Dav\u00ec S, Bracciolini G, Consolaro A, Ravelli A. IL 1 inhibition in systemic juvenile idiopathic arthritis. Front Pharmacol. 2016;6(7):467.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1001_CR84","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","volume":"46","author":"JE Cabral","year":"2025","unstructured":"Cabral JE, Wu A, Zhou H, Pham MA, Lin S, McNulty R. Targeting the NLRP3 inflammasome for inflammatory disease therapy. Trends Pharmacol Sci. 2025;46(6):503\u201319.","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"1001_CR85","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.pcl.2012.07.007","volume":"59","author":"N Laventhal","year":"2012","unstructured":"Laventhal N, Tarini B, Lantos J. Ethical issues in neonatal and pediatric clinical trials. Pediatr Clin North Am. 2012;59(5):1205\u201320.","journal-title":"Pediatr Clin North Am"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-025-01001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-025-01001-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-025-01001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:37:40Z","timestamp":1767627460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13223-025-01001-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1186\/s13223-025-01001-1","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"2"}}